作者
Sarah-Jane Dawson, Dana WY Tsui, Muhammed Murtaza, Heather Biggs, Oscar M Rueda, Suet-Feung Chin, Mark J Dunning, Davina Gale, Tim Forshew, Betania Mahler-Araujo, Sabrina Rajan, Sean Humphray, Jennifer Becq, David Halsall, Matthew Wallis, David Bentley, Carlos Caldas, Nitzan Rosenfeld
发表日期
2013/3/28
期刊
New England Journal of Medicine
卷号
368
期号
13
页码范围
1199-1209
出版商
Massachusetts Medical Society
简介
Background
The management of metastatic breast cancer requires monitoring of the tumor burden to determine the response to treatment, and improved biomarkers are needed. Biomarkers such as cancer antigen 15-3 (CA 15-3) and circulating tumor cells have been widely studied. However, circulating cell-free DNA carrying tumor-specific alterations (circulating tumor DNA) has not been extensively investigated or compared with other circulating biomarkers in breast cancer.
Methods
We compared the radiographic imaging of tumors with the assay of circulating tumor DNA, CA 15-3, and circulating tumor cells in 30 women with metastatic breast cancer who were receiving systemic therapy. We used targeted or whole-genome sequencing to identify somatic genomic alterations and designed personalized assays to quantify circulating tumor DNA in serially collected plasma specimens. CA 15-3 levels and …
学术搜索中的文章
SJ Dawson, DWY Tsui, M Murtaza, H Biggs, OM Rueda… - New England Journal of Medicine, 2013